Primrose Bio Awarded $2 Million NIH Grant to Develop Genetic Medicine Drug Design Technology
Primrose Bio has received a $2 million Direct-to-Phase II SBIR grant from the NIH's NCATS. The funding supports research into synthetic noncoding sequence elements aimed at enhancing protein expression in DNA and RNA-based medicines, leveraging its ultra-high-throughput platform.
Topics: funding genetic medicine NIH grant protein expression